Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

OBJECTIVE: We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with pre-infusion assessment; (2) over the course of treatment; and (3) possible clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Capasso, Nicola, Palladino, Raffaele, Cerbone, Vincenza, Spiezia, Antonio Luca, Covelli, Bianca, Fiore, Antonia, Lanzillo, Roberta, Carotenuto, Antonio, Petracca, Maria, Stanziola, Lucia, Scalia, Giulia, Brescia Morra, Vincenzo, Moccia, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813008/
https://www.ncbi.nlm.nih.gov/pubmed/36048265
http://dx.doi.org/10.1007/s00415-022-11350-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813008/
https://www.ncbi.nlm.nih.gov/pubmed/36048265
http://dx.doi.org/10.1007/s00415-022-11350-1

Ejemplares similares